A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

RCT (n=125) found liraglutide (3.0 mg) plus lifestyle therapy was superior to placebo plus lifestyle therapy, with regard to change from baseline in BMI standard-deviation score at week 56 (estimated difference, −0.22; 95% CI, −0.37 to −0.08; p=0.002).

SPS commentary:

Currently in the UK and EU, liraglutide is licensed only for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. 

New England Journal of Medicine